Business
Avacta Quarterly Update
Avacta Quarterly Update.
About this update from Avacta Group Plc
[{"type":"text","content":"\n\n\nAvacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives\n \nAVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025\n \nAVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026\n \nMultiple presentations at the AACR Annual Meeting highlight the promise of the pre|CISION® platform\n \nTransformation into a pure-play therapeutics company prioritizes proprietary pre|CISION® platform and extends cash runway into Q1 2026\n \n \n \nLONDON AND PHILADELPHIA - March 31, 2025 Avacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today provides a business update on progress for the first three months of 2025 and a review of upcoming milestones. \n \nChristina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta, said: \"We made a strong start to 2025, continuing to make excellent progress against all of our strategic objectives. We are very encouraged by the Phase 1 data from FAP-Dox (AVA60000) so far, which continue to show an excellent tolerability profile and increasingly durable responses in salivary gland cancers. We are now enrolling in multiple dose expansion cohorts, including triple negative breast cancer with preliminary data targeted for later in 2025.\n \n\"Our pre|CISION®-enabled exatecan program (FAP-EXd, AVA6103) also continues to progress toward a Phase 1 trial initiation early next year, underscoring our deep commitment to pioneering a novel, differentiated class of medicines to revolutionize drug delivery mechanisms. We are enthusiastic about the promise of a potent topoisomerase I inhibitor delivered in this mechanism.\"\n \npre|CISION® Medicine Pipeline\n \nFAP-Dox (AVA6000), a pre|CISION®-enabled form of doxorubicin chemotherapy, advances to Phase 1b dose expansion. During the first quarter, Avacta completed the Phase 1a dose escalation portion of the trial, demonstrating promising early efficacy and a favorable safety profile. As of the most recent data cut-off, AVA6000 continues to show improved tolerability compared to conventional dose doxorubicin, with no observed events of ...